Russia Seeking Partnership With India For Producing Covid-19 Vaccine Sputnik V: RDIF CEO

Supported by

Russia is seeking partnership with India for producing COVID-19 vaccine ‘SputnikV’, Kirill Dmitriev, the CEO of the Russian Direct Investment Fund (RDIF) said on Thursday.

Two weeks back, Russia announced the registration of the world’s first vaccine for coronavirus and the development was confirmed by President Vladimir Putin, who spoke about its efficacy and providing stable immunity.

Addressing the press briefing, Dmitriev said several nations showed significant interest in the production of the vaccine including Latin America, Asia and the Middle East. However, the country is looking for a partnership with an Indian firm.

‘The production of the vaccine is a very important issue. Currently, we are looking for a partnership with India. We believe that they are capable of producing the Gamaleya vaccine and it is very important to say that those partnerships to produce the vaccine will enable us to cover the demand that we have,’ The Hindustan Times quoted Dmitriev as saying.

The investment fund CEO also said that the country is looking forward to international cooperation for the same. The clinical trials for the Russian vaccine are also being conducted in the UAE, Saudi Arabia and most probably in Brazil as well as India, he added.

Russia has received high delivery demands from many countries and for the same, it is planning to produce the vaccine in more than five countries.

More than 20,000 people have taken part in the clinical trials of vaccines and drugs, based on human adenoviruses or human adenoviral vectors, Alexander Gintsburg, the director of the Gamaleya Research Institute of Epidemiology and Microbiology informed the media.

‘Vaccines do not contain live human adenoviruses, but human adenovirus vectors, that is, human viruses that cannot multiply in the body and are completely safe,’ Gintsburg as quoted.

Gamaleya Institute has produced the vaccine in partnership with the Russian Defence Ministry. The vaccine still needs to conduct Phase 3 clinical trials.

Also Read: Andhra Pradesh: Several Hospitalised After Ammonia Gas Leakage At Dairy Unit In Chittoor

#PoweredByYou We bring you news and stories that are worth your attention! Stories that are relevant, reliable, contextual and unbiased. If you read us, watch us, and like what we do, then show us some love! Good journalism is expensive to produce and we have come this far only with your support. Keep encouraging independent media organisations and independent journalists. We always want to remain answerable to you and not to anyone else.

Leave a Reply

Your email address will not be published. Required fields are marked *

Featured

Amplified by

P&G Shiksha

P&G Shiksha Turns 20 And These Stories Say It All

Amplified by

Isha Foundation

Sadhguru’s Meditation App ‘Miracle of Mind’ Hits 1 Million Downloads in 15 Hours, Surpassing ChatGPT’s Early Growth

Recent Stories

Secretly Recorded Spouse Conversations Admissible as Evidence: Supreme Court Clarifies in Landmark Ruling Citing Broken Trust

Nagpur Turns Sewage into ₹300 Crore a Year, Leads India in Urban Waste-to-Wealth and Biofuel Innovation

Alzheimer’s May Start in Young Adults, Not Just the Elderly: New Study Raises Early Warning

Contributors

Writer : 
Editor : 
Creatives :